PredxBio

Access our brand new White Paper here

Menu

Technology

We are the only company leveraging
unbiased spatial analytics and explainable AI to get to the
“why” in immunotherapy trials

Patients

Unbiased
Spatial Analytics

Explainable AI

Spatially Intelligent Biology

Why Unbiased Spatial Analytics?

It is now well understood that complex spatial relationships, the emergence of intermediate cell types and states, as well as communications between cells in tissues are critical components of disease progression and must be major drivers for solutions in precision pathology.

We are the only company that can

  • Identify functionally relevant transition cell states and fusion cell types
  • Discover heterogeneous microdomains associated with disease progression and outcomes
  • Reveal pathway interactions,signaling networks,potential molecular targets and drugs with microdomain-specific spatial systems pathology

Why Explainable AI?

Pathologists and disease experts require transparency and trust in applying computational and systems pathology, not black-box deep learning AI with biased heatmaps as substitutes for explanations. According to experts “xAI will be the game changer in computational pathology”.

We are the only company that can

  • Explain why a particular recommendation is made in a clinician understandable language
  • Build trust and confidence in decisions
    recommended by the algorithms
  • Deliver information and actionable knowledge
    with xAI guides to pathologists and disease
    specific clinicians who remain in full control to
    make the final decisions

White Paper

Publications

Posters

Are you leveraging the power of

Spatially Intelligent Biology?

Learn more about why explainable AI and next generation spatial analytics make a
difference in immunotherapy. 

Contact us

Subscribe to our Newsletter

* indicates required

Submit your Resume

Download Whitepaper

Download Whitepaper

B. Dusty Majumdar, PhD

CHIEF EXECUTIVE OFFICER

Linkedin-in

B. Dusty Majumdar, PhD  is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years.  Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur.  He has authored several peer-reviewed scientific publications and holds multiple patents.

Joe Camaratta

Sr. VP Business Development

Linkedin-in

Joe Camaratta specializes in medical technology innovation and commercialization, taking products from concept to clinical adoption. He held executive positions for GE Healthcare and Siemens Healthcare and built businesses in medical imaging, cardiology, and oncology. He founded and led two early stage medical technology companies that apply artificial intelligence to improve clinical decision-making.

Joe holds a Master of Science degree in Computer Science from Rutgers University and a Bachelor of Science degree in Computer Science from Drexel University. He currently serves as an advisor to the Entreprenuerial Investing Program of the Crohn’s & Colitis Foundation, and the University Science Center QED Program focused on commercialization of academic innovations

Bruce Campbell, MS

VP Software Engineering

Linkedin-in

Bruce leads the software engineering and quality assurance teams at PredxBio. As the VP of Software Engineering, he is responsible for analytical infrastructure, product development and the commercialization of machine learning, image processing, and computational biology algorithms. Prior to joining PredxBio, Bruce was at IBM and Xylem in global Director of Data Science roles. He has over 20 years of experience in digital pathology algorithms and is highly motivated to deliver care through digital and computational pathology. He has multiple successful FDA 510k device applications, and multiple CLIA certified algorithms deployed in clinical practice.

Bruce holds a BS in Physics and MS in Applied Mathematics from the University of Rochester, an MS in Statistics from North Carolina State University, and is currently pursuing graduate mathematics studies at The Ohio State University. Bruce loves the outdoors. You can find him hiking and rock climbing in Appalachia.